Drugmakers Bharat Biotech and GSK will reduce the price of their malaria vaccine, Mosquirix, to $5 per dose by 2028, more than halving the current cost. This price cut, driven by process improvements and expanded production, aims to improve access to the vaccine in sub-Saharan Africa, where malaria deaths are high. Gavi supports the vaccine’s rollout in twelve African countries.
Categories
Finance/Money
Bharat Biotech, GSK to halve price of malaria vaccine by 2028
